Hijioka, Susumu http://orcid.org/0000-0002-0394-6876
Sakuma, Keiichiro
Aoki, Masahiro
Mizuno, Nobumasa
Kuwahara, Takamichi
Okuno, Nozomi
Hara, Kazuo
Yatabe, Yasushi
Funding for this research was provided by:
Aichi Cancer Research Foundation
Article History
Received: 25 June 2018
Accepted: 2 October 2018
First Online: 11 October 2018
Compliance with ethical standards
:
: Susumu Hijioka has received speaker honoraria from Novelphama, Novartis, and Teijin Pharma. Nobumasa Mizuno has received research funding from AstraZeneca, Zeria Pharmaceutical, Taiho Pharmaceutical, Merck Serono, Eisai, NanoCarrier, MSD, Dainippon Sumitomo Pharma, and Novartis. Keiichiro Sakuma, Masahiro Aoki, Takamichi Kuwahara, Nozomi Okuno, Kazuo Hara, and Yasushi Yatabe have no conflicts of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.